

Product Data Sheet

Product Name: Fulvestrant-d3

Cat. No.: GC40241

Chemical Properties

Cas. No.

SMILES OC1=CC=C2C(C[C@@H](CCCCCCCCCS(CCCC(F)(F)C(F)(F)F)=O)[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC([2H])([2H])[C@]4([2H])O)=C1


Formula C32H44D3F5O3S M.Wt 609.8

Solubility DMF: 25 mg/ml, DMSO: 20 mg/ml, Ethanol: 25 mg/ml Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Background

Fulvestrant-d3 is intended for use as an internal standard for the quantification of fulvestrant by GC- or LC-MS. Fulvestrant is a selective estrogen receptor degrader (SERD) that downregulates and degrades estrogen receptor α (ER α). It binds to rat uterine ER with an IC50 value of 44.8 nM and prevents uterine weight increases induced by estradiol in immature rats (ED50 = 0.06 mg/kg per day) but has no effect on uterine weight alone. It also decreases uterine weight in adult rats without affecting the production of luteinizing and follicle-stimulating hormones and prolactin. Fulvestrant inhibits the growth of ER-positive MCF-7 human breast cancer cells but not ER-negative BT-20 cells when used at a concentration of 1 μ g/ml. It also prevents tumor growth in MCF-7 and Br10 breast

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

cancer mouse xenograft models when used at a single dose of 5 mg per animal. Fulvestrant is neuroprotective in vitro against neurotoxicity induced by glutamate- and amyloid- β (1-42) (A β 42) in primary rat hippocampal cells. Formulations containing fulvestrant have been used in the treatment of estrogen-sensitive breast cancer.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA